Clinical Trials
2 trialsNCT04151563 2023-12-19
CheckMate 79X
Bristol-Myers Squibb
Phase 1/2 Withdrawn
NCT02109016 2019-07-29
A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
Clovis Oncology, Inc.
Phase 2 Terminated